Microglia and mast cells: two tracks on the road to neuroinflammation
Abstract
One of the more important recent advances in neuroscience research is the understanding that there is extensive communication between the immune system and the central nervous system (CNS). Proinflammatory cytokines play a key role in this communication. The emerging realization is that glia and microglia, in particular, (which are the brain's resident macrophages), constitute an important source of inflammatory mediators and may have fundamental roles in CNS disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Microglia respond also to proinflammatory signals released from other non‐neuronal cells, principally those of immune origin. Mast cells are of particular relevance in this context. These immunity‐related cells, while resident in the CNS, are capable of migrating across the blood‐spinal cord and bloodbrain barriers in situations where the barrier is compromised as a result of CNS pathology. Emerging evidence suggests the possibility of mast cell‐glia communications and opens exciting new perspectives for designing therapies to target neuroinflammation by differentially modulating the activation of non‐neuronal cells normally controlling neuronal sensitization, both peripherally and centrally. This review aims to provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of microglia, neuroimmune interactions involving mast cells, in particular, and the possibility that mast cell‐microglia crosstalk may contribute to the exacerbation of acute symptoms of chronic neurodegenerative disease and accelerate disease progression, as well as promote pain transmission pathways. We conclude by considering the therapeutic potential of treating systemic inflammation or blockade of signaling pathways from the periphery to the brain in such settings.—Skaper, S. D., Giusti, P., Facci, L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 26, 3103–3117 (2012). www.fasebj.org
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the masitinib phase III clinical trial (NCT01872598), the drug combination reached the clinical phase without reported evidence of strong in vivo validation of synergistic or additive effects.
“Apparently, in this case, the drug combination reached the clinical phase without reported evidence of a strong in vivo validation of the synergic or additive effects involved.75”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [75]
The citation lists haven’t been fetched yet
References 240 · Cited by 235
- Authors
- Skaper, S. D., Giusti, P., & Facci, L.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Skaper, Stephen D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2012-04-19
- Volume
- 26
- Issue
- 8
- Pages
- 3103-3117
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2157921902
- Cited by
- 235
- References
- 240
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 14 · 2023: 14 · 2022: 8 · 2021: 16 · 2020: 18 · 2019: 15 · 2018: 12 · 2017: 20 · 2016: 20 · 2015: 22 · 2014: 33 · 2013: 27 · 2012: 8
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Fondazione Cassa di Risparmio di Padova e Rovigo
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Keywords
- microglia, mast cells, neuroinflammation, neuroimmune interactions, inflammatory cytokines, neurodegenerative diseases, neuropathic pain, epilepsy, blood-spinal cord barrier, systemic inflammation, neuroprotection
- MeSH terms
- Animals, Central Nervous System, Humans, Immunity, Innate, Inflammation, Mast Cells, Neuroglia, Pain, Receptors, Purinergic, Spinal Cord, Microglia, Inflammation Mediators, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review